A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01138-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849310365982130176 |
|---|---|
| author | Timothy E. Albertson Caitlin Hansen Juleen Gayed Xia Xu Ye Feng Hua Ma |
| author_facet | Timothy E. Albertson Caitlin Hansen Juleen Gayed Xia Xu Ye Feng Hua Ma |
| author_sort | Timothy E. Albertson |
| collection | DOAJ |
| format | Article |
| id | doaj-art-415f1d2f4d8b4b08a0b01550f551ca66 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-415f1d2f4d8b4b08a0b01550f551ca662025-08-20T03:53:46ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-04-011451137114110.1007/s40121-025-01138-xA Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”Timothy E. Albertson0Caitlin Hansen1Juleen Gayed2Xia Xu3Ye Feng4Hua Ma5UC Davis Medical CenterVaccine Research and Development, Pfizer IncVaccine Research and Development, Pfizer LtdVaccine Research and Development, Pfizer IncVaccine Research and Development, Pfizer IncVaccine Research and Development, Pfizer Inchttps://doi.org/10.1007/s40121-025-01138-xBNT162b2Clinical trialsCOVID-19MyocarditisPericarditisSafety |
| spellingShingle | Timothy E. Albertson Caitlin Hansen Juleen Gayed Xia Xu Ye Feng Hua Ma A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” Infectious Diseases and Therapy BNT162b2 Clinical trials COVID-19 Myocarditis Pericarditis Safety |
| title | A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” |
| title_full | A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” |
| title_fullStr | A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” |
| title_full_unstemmed | A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” |
| title_short | A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination” |
| title_sort | response to letter to the editor regarding serum troponin i assessments in 5 to 30 year olds after bnt162b2 vaccination |
| topic | BNT162b2 Clinical trials COVID-19 Myocarditis Pericarditis Safety |
| url | https://doi.org/10.1007/s40121-025-01138-x |
| work_keys_str_mv | AT timothyealbertson aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT caitlinhansen aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT juleengayed aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT xiaxu aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT yefeng aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT huama aresponsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT timothyealbertson responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT caitlinhansen responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT juleengayed responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT xiaxu responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT yefeng responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination AT huama responsetolettertotheeditorregardingserumtroponiniassessmentsin5to30yearoldsafterbnt162b2vaccination |